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ABSTRACT PAGE
The neuropeptides orexin A and B (also known a s hypocretin 1 and 2) have been
implicated in the regulation of feeding behavior, emotional arousal, and sleeping and
waking behaviors. Previous research has indicated that orexin neurons projecting from
the hypothalamus excite basal forebrain cholinergic neurons, resulting in increased
awakefulness (Eggermann et al., 2001). The basal forebrain cholinergic system has
been implicated in the regulation of attention (McGaughy et al., 1996). Collectively, these
results suggest that orexins might play a role in attentional processing. The current
studies a sse sse d the effects of systemic and intrabasalis administration of an orexin-1
receptor anagonist, SB-334867 on attentional performance. Rats were trained on an
attention task that required discrimination between visual signals (500 ms, 100 ms, and
25 ms) and non-signals. In Experiment 1, the rats were each given three injections: a
vehicle solution and two levels of SB-334867, 1.0 mg/kg and 5.0 mg/kg, counterbalanced
across subjects. The results revealed an interaction for signal duration and dose. Visual
detection at the 500 ms signal duration w as impaired at the highest dose; in addition,
performance at the 25 ms signal duration improved at the highest dose. In Experiment 2,
rats were given four intrabasalis infusions: a vehicle solution and three d o ses of SB334867, 0.15 pG/side, 0.33 pG/side, and 0.6 pG/side. No significant effects were found
for dose. The data suggest that orexin A does play a role in regulating attention, though
the link might be more complicated than previously thought.
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As humans, we have a basic idea of what attention is and can report when
it is being used. However, understanding the specific functions and processes of
attention is more difficult. It is only relatively recently that scientific innovations
have allowed scientists to map out some of the specific mechanisms of attention,
as well as what brain regions make up the attentional system.
Classic attention research described attention as a process similar to
decision-making (Broadbent & Gregory, 1963). Two models of attention were
developed by researchers during this time: the early-selection model and the lateselection model (Broadbent & Gregory, 1963; Deutsch & Deutsch, 1963). Earlyselection theory hypothesizes that selective attention places more emphasis on the
selected stimulus, not by blocking out the unattended stimulus, but by reducing its
intensity. This process takes place before the brain analyzes the content of the
stimulus. Late-selection models hypothesize that the brain analyzes the content of
i

both stimuli but filters out irrelevant information. Thus, unattended stimuli never
reach a conscious level of cognition.
Attention has been compared to shining a spotlight on the object which is
being scrutinized (Cavanaugh, 2004). Only the object within the spotlight has
been selected for higher processing, and objects outside of the spotlight are not
further processed. Multiple spotlights, or areas of selection, can be functioning at
once. By having these specific areas o f selection, the brain can filter out
unimportant stimuli and send the more important information on for deeper
processing. The attentional system displays limited capacity and acuity during
selection tasks (Cavanaugh, 2004; Carr, 2004). One's ability to focus on multiple
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objects is limited, and the detail with which one can describe the object decreases
as the load on the attentional system increases. Increased numbers o f distractors
can inhibit one's ability to focus efficiently on the selected object, compromising
deeper processing.
The neuroanatomy of attention was first explored using electrode
recordings in the superior colliculus during visual attention shifts in the macaque
monkey (Wurtz & Goldberg, 1972). The first imaging studies offered more
insight into the neural systems that underlie attentional processing, including the
posterior parietal lobe and the anterior cingulate, both of which were found to be
important for target detection in attention tasks (Posner & Petersen, 1990).
Since then, numerous other neural systems have been implicated in the
regulation of attentional processing. A growing body o f literature has implicated
the cholinergic system as a key neurotransmitter within the attentional system.
Specifically, cholinergic projections from the basal forebrain, in particular the
nucleus basalis of Meynert, to the neocortex are implicated in attention.
Basal Forebrain Corticopetal Cholinergic Neurons and Attention in the Rat
Various tasks have been designed to measure attentional performance in
rats. Researchers often use a five-choice serial task, which is specifically
designed to tax attentional demands (Robbins, 2002). In this task, rats are required
to monitor five locations for a 0.5 s visual signal presentation. A nose poke into
an aperture underneath the signal presentation location (as measured by infrared
photobeams) is scored as a correct response and results in a food reinforcement.
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An incorrect nose poke or no response results in a five second time out. This task
tests the ability of the rat to maintain a level of spatial attention over 30 minutes.
Excitotoxic lesions to the basal forebrain result in reduced choice accuracy
on this task, perhaps due to the removal of cholinergic input to the neocortex
(Robbins, Everitt, Marston, Wilkinson, Jones, & Page, 1989). However, due to
the nonspecificity of excitotoxic lesions, the learning impairments found in the
five-choice serial reaction time task were not necessarily a result of the loss of
cholinergic neurons. GABAergic and glutamatergic neurons are much more
numerous within the basal forebrain than cholinergic neurons (Zaborsky,
Gaykema, Swanson, & Cullinan, 1997). Since excitotoxic lesions completely
destroy neurons within the target area and fibers o f passage, it is reasonable to
speculate that it is the loss o f another neuronal system, or the cumulative loss of
the neurons within the basal forebrain, that decrease task performance (Everitt &
Robbins, 1997).
Immunotoxins have allowed more targeted lesions of specific
neurotransmitter systems. Specifically, researchers developed the cholinotoxin
192 IgG-saporin, which selectively targets the p75 nerve growth factor receptors
(Waite, Chen, Wardlow, Wiley, Lappi, & Thai, 1995). This nerve growth factor is
expressed by cortically-projecting cholinergic neurons within the basal forebrain
and some Purkinje cells within the cerebellum. Thus, this cholinotoxin
selectively destroys neurons expressing p75 and leaves all other neurons intact.
This allows for 192 IgG-saporin to be infused into cortical regions, such as the
preffontal cortex (PFC), and only destroy cholinergic neurons within the basal

forebrain, which receives projections from the PFC. These immunotoxic lesions
reduce levels of choline acetyltransferase by up to 90% with increasing doses
(Holley, Wiley, Lappi, & Sarter, 1994; Waite et al., 1995). On a behavioral level,
extensive intrabasalis lesions caused by 192 IgG-saporin resulted in decreased
choice accuracy and an increase in omissions on a five-choice serial reaction time
task (McGaughy, Dailey, Morrison, Everitt & Robbins, 2002).
In addition, 192 IgG-saporin has been shown to cause behavioral deficits
in other tasks designed to tax attentional demands (Bushnell, Oshiro, & Padnos,
1997; McGaughy & Sarter, 1998; Arnold, Burk, Hodgsom, Sarter, & Bruno,
2002). Intrabasalis infusions of 192 IgG-saporin decreased signal detection on a
visual discrimination task designed to have high attentional demands (McGaughy,
Kaiser, & Sarter, 1996). This task is comprised of signal and non-signal trials.
The signal trials are comprised of three signal durations, 500 ms, 100 ms, and 25
ms. Rats are trained to press one lever in response to a signal presentation, and
trained to press another lever in response to a non-signal or “blank” trial.
Compared to the five-choice serial task, the visual discrimination task minimized
the spatial and locomotor aspects of the task, while still being a valid measure of
attentional performance (McGaughy & Sarter, 1995). In addition, the task is very
sensitive to cholinergic manipulations. Rats that received 192 IgG-saporin lesions
displayed significantly impaired visual detection of all signal durations. However,
the percentage of correct lever responses to non-signal trials was not affected,
indicating that the rats were still able to perform within the rules of the task.
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Neuroanatomy o f the Orexinergic System
In the late 1990’s, two groups of researchers independently discovered a
population of neuropeptides later known as orexin A and B (hypocretin 1 and 2),
(Sakurai, Amemiya, Ishii, Matsuzaki, Chemelli, Tanaka, Williams, Richardson,
Kozlowski, Wilson, Arch, Buckingham, Haynes, Carr, Annan, McNulty, Liu,
Terrett, Elshourbagy, Bergsma, & Yanagisawa, 1998; de Lecea, Kilduff, Peyron,
Gao, Foye, Danielson, Fukuhara, Battenberg, Gautvik, Bartlett, Frankel, van den
Pol, Bloom, Gautvik, Sutcliffe, 1998). Orexin A and B are produced in the lateral
hypothalamus and medially contiguous perifomical area (Sakurai, 2007; Mignot,
Taheri, & Nishino, 2002). The orexin system projects to numerous brain regions
including the locus coeruleus (LC), the preoptic area, paraventricular nucleus of
the thalamus, basal forebrain, and spinal cord (Sakurai, 2007; Chemelli, Willie,
Sinton, Elmquist, Scammell, Lee, Richardson, Williams, Xiong, Kisanuki, Fitch,
Nakazato, Hammer, Saper, & Yanagisawa, 1999). Orexin A and B bind
differentially to the two subtypes of orexin receptors, Orexin-1 and Orexin-2
(Sakurai et al., 1998). Orexin A binds to Orexin-1 receptors with high affinity,
while Orexin B binds with 100- to 1000-fold lower affinity. The orexin-2 receptor
has a high affinity for both peptides.
The hypothalamus is important for regulating metabolic functions, as well
as hunger, thirst, and circadian rhythms (Sakurai, 2007). Orexins are
neuroexcitatory in nature, in that they increase axonal activity, specifically within
the hypothalamus (de Lecea et al, 1998). They have been implicated in the
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regulation of energy homeostasis, hormone secretion, and feeding behaviors. In
addition, orexins seem to play an important role in the maintenance of waking and
sleeping patterns, as well as arousal states.
Orexin neurons have been implicated in autonomic homeostasis and
hormone secretion. Orexins project to brain areas thought to be important for the
regulation o f heart rate and blood pressure, including the ventrolateral medulla
and the locus coeruleus (Dampney, 1994). Orexins also might play a role in the
regulation of body temperature, as they project to the raphe magnus and
subcoeruleus (Werner & Bienek, 1990). Lesions o f the rostral raphe nuclei have
been shown to cause a loss of thermoreactiveness within preoptic neurons. In
addition, the location of orexinergic projections also supplies evidence that these
neuropeptides are important in hormone secretion. Orexin neurons project to the
arcuate nucleus, an area that houses numerous populations of hormone-secreting
neurons, including gonadatropin-releasing hormone (Iqbal, Pompolo, Sakurai, &
Clarke, 2001). Orexin A has been shown to decrease concentrations of growth
hormone and prolactin, while Orexin B seems to have a direct effect on the
function of the pituitary, adrenal, and pineal glands (Mikkelsen et al., 2001;
Randeva, Karteris, Grammatopoulos, & Hillhouse, 2001; Samson & Taylor,
2001).
When first discovered, one of the primary functions of orexins was
thought to be related to feeding behavior (Sakurai et al., 1998). Orexin neurons
express leptin receptors, a peptide hormone encoded on the obese gene that
suppresses appetite via action within the hypothalamus (Hakansson, de Lecea,
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Sutcliffe, Yanagisawa, & Meister, 1999; Horvath, Diano, & Van den Pol, 1999).
Leptin knockout mice (ob/ob) also have decreased levels o f the orexin precursor
preprohypocretin mRNA (Yamamoto et al., 1999). In addition, periods of fasting
increase orexin peptides levels within the hypothalamus (Sakurai et al., 1998;
Mondal, Nakazato, Date, Murakami, Yanagisawa, & Matsukura, 1999).
Orexin’s effects on feeding have also been seen through behavioral
studies. Short-term food consumption in rats has been found to be increased
following intracerebroventricular administration of both orexin A and B (Sakurai
et al., 1998). Similarly, orexin B increases food consumption in sheep (Sartin et
al., 2001). Feeding behavior can also be increased following the intracranial
administration o f orexin A to various brain regions involved in feeding, including
the lateral hypothalamus, perifomical area, and the dorsomedial hypothalamic
nucleus. However, many researchers believe that orexin’s role in feeding is not as
important as was first believed. Increases in feeding behavior could be a
byproduct of orexin’s role in the sleep-wake cycle (Yamanaka, Sakurai,
Katsumoto, Yanagisawa, & Goto, 1999; Fujiki, Yoshida, Ripley, Honda, Mignot,
& Nishino, 2001). Orexins seem to promote wakefulness, which could in turn
cause greater food intake.
Pathology of orexin neurons has been implicated in the sleep disorder
narcolepsy with cataplexy. Narcolepsy is a rare neurological disorder
characterized by excessive daytime sleepiness, sleep paralysis, hypnogogic
hallucinations, and in some cases, cataplexy (NINDS, 2008). Orexin’s role in the
sleep-wake cycle was first discovered through genetic mapping projects
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concerning the defective canine narcolepsy gene (Lin et al., 1999). The absence
of orexins within the cerebrospinal fluid is a characteristic o f narcolepsy (Nishino,
Ripley, Overeem, Lammers, & Mignot, 2000; Ripley et al., 2001). Ripley and
colleagues found that 37 out o f 42 narcoleptics studied did not have detectable
levels of orexins within their cerebrospinal fluid.
Orexin neurons within the lateral and perifomical hypothalamus receive
projections from the superchiasmatic nucleus (SCN), which generates the
circadian rhythm (Abrahamson, Leak, & Moore, 2001). Orexin levels within the
brain fluctuate throughout the circadian rhythm, becoming more active during
wakefulness. Sleep deprivation has been shown to increase orexin levels even
further, suggesting that one o f the primary functions o f orexin is to promote
wakefulness (Yoshida et al., 2001).
Activation of monoamine neurons in the LC, dorsal raphe (DR), and
tuberomamillary nucleus (TMN) are critical for maintaining wakefulness, and are
referred to as REM-off cells. These neurons are most active during wakefulness,
less active during non-REM sleep, and are completely inactive during REM sleep
(Saper, Chou, & Scammell, 2001; Mileykovskiy, Kiyashchenko, & Siegel, 2005).
Administration of orexin A and B increases the activity o f histaminergic neurons
within the TMN, and orexin A has an excitatory effect on noradrenergic neurons
within the LC and seratonergic neurons in the DR (Hagan et al., 1999). The
excitation o f these monoamines prolongs their activity, which decreases REM
sleep and increases arousal.
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Behaviorally, intracerebroventricular injections of orexin A have been
found to increase arousal as measured by increased locomotion in an X-maze and
increased startle responses (Hagan et al., 1999). In addition, support for orexin’s
role in cognitive processing has been shown in sleep-deprived rhesus monkeys
(Deadwyler, Porrino, Siegel & Hampson, 2007). Systemic and intranasalis
administration of orexin A significantly improved performance on a delayed
match-to-sample task following 30 to 36 hours of sleep deprivation. No
improvements were seen after drug administration following normal sleep.
Basal Forebrain Cholinergic Neurons and Orexins
Neuroanatomical research has found numerous axonal hypothalamic
projections onto cholinergic neurons in the basal forebrain (Cullinan & Zaborsky,
1991). Fadel, Pasumarthi, and Reznikov (2005) found orexin-immunoreactive
fibers positioned closely to cholinergic neurons, suggesting that orexin projections
from the hypothalamus map directly onto cholinergic neurons within the basal
forebrain. Infusions of orexin A into the basal forebrain result in increased
wakefulness in rats (Espana, Baldo, Kelley, & Berridge, 2001). Electrodes
monitored brain wave patterns during sleeping and waking cycles, showing that
total time awake increased, and total time spent in slow wave sleep and rapid eye
movement sleep decreased. More specifically, Eggermann and colleagues (2001)
found that orexins excite cholinergic neurons in the basal forebrain, resulting in
increased cortical activation and awakefulness.
Fadel and colleagues (2005) used microdialysis to assess the effect of
orexin A on cholinergic release in the PFC. Levels of ACh in the PFC

10

significantly increased after intra-basalis administration of orexin A. Infusions of
orexin A directly into the PFC did not increase PFC ACh. These data suggest that
intrabasalis infusions of orexin A can affect levels of ACh in brain areas
important for various cognitive functions, including attention. Fadel and
Frederick-Duus (2008) theorize that orexins modulate basal forebrain ACh in
response to visual stimuli that are relevant to one’s physiological state, including
hunger or thirst level. This would be especially relevant to the current study, in
which appetitive motivation is being assessed using a visual discrimination task.
The Current Experiments
The current experiments use a previously validated attention task. The task
has been tested with various manipulations (McGaughy & Sarter, 1995),
including background noise, high event rates, and event asynchrony. During this
task, rats are required to visually discriminate between three signal durations and
a nonsignal trial, and then respond by pressing the correct lever. The introduction
o f “background noise” (in the form of a flashing house light) resulted in impaired
signal detection between signal and non-signal trials, indicating that flashing light
distracted the rats from achieving optimal performance. In addition, the flashing
houselight resulted in increased rate o f poorer signal detection of the shortest
signal duration during the last block of trials. This vigilance decrement could be a
form of attentional fatigue. Rats often respond to the shortest signal duration as a
non-signal trial, by pressing the incorrect lever. This signal length could require
more attentional resources to detect, thus being affected by a vigilance decrement
before the other signal durations, especially in the presence of a distraction. High
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event rates, or a higher number of trials per minute (defined as having 9 ± 3 s in
between trials), also augmented this vigilance decrement. In addition, event
asynchrony was used to test the rat’s ability to time trial onset. To achieve this,
the inter-trial interval (ITI) was varied across trials (12 ± 6 s). Highly varied ITI
had no effect on attentional performance, as it did not affect signal detection or
the number o f trials omitted (not responded to). Thus, it is unlikely that the rats
were timing trial onset. McGaughy and Sarter also used animal age as a variable
to test task validity. Normal aging results in attentional deficits (Verhaeghen &
Cerella, 2002). Twenty month old rats were less able to discriminate between the
shortest signal duration and the nonsignal trials as compared to young rats, as
displayed by an increased number of incorrect lever responses following the
shortest signal duration. However, no deficits were found during the nonsignal
trials, indicating that the rats knew the rules o f the task. The previous data
support that the current task is a valid measure of attention in the rat.
To examine differences in cortical ACh release during and after task
performance, Arnold and colleagues (2002) compared two control procedures that
did not explicitly tax attention to the current task. First, a basic operant control
task using a fixed ratio schedule of 9, but in which only 60% of these intervals
were rewarded; this task was designed to explore the effects o f simple operant
responding. The second task was designed to assess the effects of lever extension
as a prompt for responding. This task mirrored the first control procedure, except
that only one lever was extended into the chamber. ACh levels within the cortex
were measured using microdialysis during and after task performance. The two
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control procedures resulted in dramatically smaller increases in cortical ACh
efflux (about 50%) compared to increases following the current task (about
140%). These data support that the current task requires high attention demands
which in turn elevate cortical ACh levels.
Specifically important for the current experiments, visual signal detection
in this task has been shown to be sensitive to various basal forebrain cholinergic
manipulations, including cortical cholinergic deafferentation produced by
intrabasalis infusions of 192 IgG-saporin (McGaughy et al., 1996). Moreover,
signal detection in this task is also sensitive to other manipulations of basal
forebrain neurons that depress cortical ACh release, including intrabasalis
infusions of an NMDA receptor antagonist (Turchi & Sarter, 2001) or a
benzodiazepine receptor agonist (Holley, Turchi, Apple, & Sarter, 1995;
McGaughy & Sarter, 1995).
The current experiments assessed the effects o f systemic and intrabasalis
administration of the orexin-1 receptor antagonist SB-334867. While orexin A
has been implicated in increased wakefulness and cognitive functioning, an
orexin-1 receptor antagonist was used in this study due to the ceiling effect
observed in the attentional task used. Rats often perform with over 90% accuracy
on the longer signal durations, making attentional enhancements difficult to
observe. Experiment 1 investigates the effects of systemic injections of SB334867. Administration of the orexin-1 receptor antagonist was expected to
decrease ACh release within the cortex, resulting in impaired visual signal
detection. Experiment 2 investigates the effects of localized infusions of SB-

13

334867 into the basal forebrain. Infusions of the orexin-1 receptor antagonist were
expected to result in impaired signal detection, similar to the impaired signal
detection expected in Experiment 1.
Experiment 1
Methods
Subjects. Subjects were 16 male Long-Evans rats, approximately two
months old at the beginning of the experiment (Charles River Laboratories, Inc.,
Wilmington, MA). All animals were experimentally naive. The rats were housed
individually in a temperature- and humidity-controlled environment with a 14/10
hour light/dark cycle. All behavioral testing took place between 0900 and 1200,
five days per week. Animals were water restricted for the duration of the
behavioral testing, only receiving water during the task and for 30 minutes after
the testing session. The rats were allowed free access to water on days when no
behavioral testing occurred. Food was available ad libitum for the duration of
experiment. The experimental protocol was approved by the Institutional Animal
Care and Use Committee at the College of William and Mary, and all animals
were handled according to Guidelines for the Care and Use of Laboratory
Animals as set forth by the National Institutes o f Health (National Research
Council, 1996).
Apparatus. The rats were trained in 12 chambers each housed within a
sound-attenuating box. One side of the chamber contained two retractable levers,
a water port with an automated water delivery dipper (0.01 ml) located between
the two levers, and three panel lights. One panel light was positioned directly

14

over each retractable lever, and one panel light was centrally located above the
water port. Only the centrally located panel light was used for this experiment. A
house light was located on the other side of the chamber. The house light
remained illuminated during all behavioral training and testing. Luminance levels
o f the house and panel lights have been previously described (Burk, 2004).
Behavioral training and testing programs were administered by a personal
computer using the Med-PC version IV software.
Behavioral training procedures. The house light was illuminated during
all training procedures and the test task. During the first stage of training, the
retractable levers were extended into the chamber at all times. The water dipper
was raised after each lever press. To discourage side bias, five consecutive
presses on a lever resulted in the discontinuation of water access until the other
lever was pressed. Rats were required to meet a criterion of 120 lever presses per
session for three sessions in order to move on to the next training stage. During
the second training stage, the rats were trained to discriminate between signals (1
s illumination of the panel light) and non-signals (no illumination of the light).
After a signal or non-signal was presented, the retractable levers were extended
into the chamber. Half o f the rats were trained to press the left lever after a signal
presentation, which would be scored as correct, or a hit, and water access would
be provided. If the rat pressed the right lever after a signal trial, this was
considered to be a miss. Following a non-signal presentation, a press on the right
lever was considered to be a correct rejection and water access was provided. A
press to the left lever was considered to be a false alarm. The rules o f the task
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were reversed for half of the rats, meaning that the right lever was the correct
response following signal presentation and the left lever was the correct response
following a non-signal. Incorrect choices were followed by a correction trial that
was identical to the previous trial; three incorrect choices in a row resulted in a
forced choice trial in which only the correct lever was extended for 90 s. During
the forced choice trial, the panel light remained illuminated for the duration of the
lever extension. For all trials, if no lever press was made within three seconds
after lever extension, the trial was scored as an omission. The inter-trial interval
(ITI) for this stage of training was 12±3 s, to reduce anticipation of the beginning
of the next trial. Criterion for completion of this stage of training was set at 70%
hits and 70% correct rejections for three consecutive sessions.
During the final version of the task, three signal durations were used: 500
ms, 100 ms, and 25 ms. The presentation of these signal durations was randomly
varied. There were a total of 162 trials each session (81 signal, 81 non-signal). In
addition, the ITI was reduced to 9±3 s. No correction trials or forced choice trials
were used during the final task. The animals were trained on this task until the
criterion of 70% hits on the 500 ms signal and 70% correct rejections for three
consecutive sessions was met. Once criterion was reached, drug administration
for the present experiment began.
Procedures fo r SB-334867 administration. The orexin-1 receptor
antagonist SB-334867 (Tocris Bioscience, Ellisville, MO) was suspended in a
vehicle solution o f 1.0 mL saline, 200 mg Hydroxy-beta-cyclodextran, and 125
pL 100% DMSO. After the addition o f SB-334867, the solution was vortexed for
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30 minutes prior to injection. Fresh vehicle solution was prepared the day of
injection, with excess solution being discarded after use.
The rats received three i.p. injections: vehicle solution, 1.0 mg/kg SB334867, and 5.0 mg/kg SB-334867 in a counterbalanced order. All injections
were administered immediately prior to the beginning of each testing session.
The testing program had a 10-min delay included at the beginning of each testing
session to allow time for the drug to cross the blood-brain barrier. Satiety studies
have shown that significant effects of SB-334867 begin 20 minutes after i.p.
administration and peak after one hour (Rodgers, Halford, Nunes de Souza, Canto
de Souza, Piper, Arch, Upton, Porter, Johns, & Blundell, 2001). At least two days
o f behavioral training took place between drug administrations in order to
reestablish baseline task performance, which was defined as three consecutive
days o f 70% hits on the 500 ms signal and 70% correct rejections.
Behavioral measures and statistical analyses. The number of hits (H),
misses (M), correct rejections (CR), false alarms (FA), and omissions were
recorded for each testing session. Each session was divided into three blocks
(trials 1-54, trials 55-108, and trials 109-162) to assess the effect of the drug
within each session; sessions were also divided by signal duration (500 ms, 100
ms, and 25 ms). The relative number o f hits per block at each signal duration, as
well as the overall session was calculated as (H/H+M), and the relative number of
correct rejections per block and for the overall session was calculated as
(CR/CR+FA). Omissions were analyzed separately from measures of response
accuracy. The mean response latencies for hits, misses, correction rejections, and
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false alarms were calculated and analyzed using as multi-factor ANOVA with the
trial outcomes as factors.
The relative number of hits was analyzed using a repeated-measures
analysis o f variances (ANOVA) with the factors of signal duration, block, and
dose. The relative number of correct rejections was also analyzed using a
repeated-measures ANOVA with the factors of block and dose.
Results
The data reported here are from the 13 rats that maintained stable
performance levels in between drug administration sessions. This study assessed
the effects of systemic administration of orexin antagonist SB-334867 on
performance on an attention task. A repeated measures ANOVA on the relative
number of hits for the three signal durations found a significant main effect for
signal duration (F(2, 24) = 212.9, p < .001). Rats exhibited signal durationdependent accuracy, with the hit rate higher following longer signal durations
(Figure 1). For hits, a significant interaction was found for signal duration and
dose (F(4,48) = 3.06,p < 0.05). Compared to vehicle administration, the hits
following 5.0 mg/kg SB-334867 were lower on 500 ms signal trials (t( 12) = 2.36,
p < 0.05). The hit rate to the 25-ms signal was elevated following 1.0 mg/kg SB334867 compared to vehicle administration (t(12) = 2.58,p < 0.05; Figure 2). No
other significant effects were found for the relative hits. A repeated-measures
ANOVA for the relative number o f correct rejections found no significant main
effects for block or dose (Figure 3). No significant effects were found for lever
press latency or omissions.
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Discussion
Experiment 1 investigated the effect of the orexin-1 receptor antagonist
SB-334867 on performance on an attention task. Systemic administration of the
orexin-1 antagonist resulted in decreased signal detection at the highest dose (5.0
mg/kg SB-334867) for the longest signal duration (500 ms). In addition, signal
detection of the shortest signal duration (25 ms) was improved at 1.0 mg/kg SB334867 dose. A trend showing increased signal detection of the 25 ms signal
flowing the highest dose was also found. No deficits were found for the non
signal trials as the number of correct rejections did not change across dose. The
lack o f drug-induced or, in previous experiments, lesion-induced effects on
detection of non-signals has been used as an indicator that the subjects displayed
no lever bias and were continuing to respond based on the task rules (McGaughy
et al., 1996). No severe motor or motivational deficits due to the effects of the
drug were detected, as evidenced by the lack of change in response latencies or
trial omissions.
The above factors are important to consider when interpreting the changes
in signal detection found. The decrease in signal detection at the 500 ms signal
duration indicates that the highest dose of SB-334867 may decrease cortical ACh
release. McGaughy & Sarter (1998) found a similar pattern after moderate
ablations o f cortical cholinergic inputs in 192 IgG-saporin-lesioned rats; only the
hit rate to the longest signal duration (also 500 ms) was impaired. Administration
o f SB-334867 might have resulted in a moderate impairment of the cholinergic
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system, resulting in the pattern of detection deficits at the longest signal duration
reported here.
One unexpected result in the present experiment was that 1.0 mg/kg SB334867 elevated detection of the 25 ms signal. This increase in signal detection is
not necessarily indicative of attention enhancements. Signal detection remained
stable at the 100 ms signal duration for all doses; if attentional enhancement took
place, increased signal detection could be expected at the 100 ms signal duration
as well. In addition, signal detection was decreased following the 500 ms signal.
Thus, the reason for this improved signal detection remains speculative. The
signal-driven and cognitive modulation hypotheses of signal detection offer
potential explanations for the current results, specifically the improved detection
at the 25 ms signal duration (Sarter, Hasselmo, Bruno, & Givens, 2005).
According to this model, cortical acetylcholine release, functioning in response to
signal properties and cognitive context, is involved in determining whether a
particular event is responded to as a signal or non-signal. In the current study,
rats appear to typically respond to the 25 ms signal as a non-signal during baseline
task performance, resulting in a low number of hits at this signal duration. The
average percentage of correct responses at the 25 ms signal following the vehicle
dose was 21%, indicating on 79% of the trials, rats were responding to the 25 ms
signal as if it was a non-signal. Administration of SB-334867 may have
decreased cortical ACh release, altering this top-down process, changing the rat’s
criterion for identifying events as signals. A “riskier” criterion may have led to
the increase in hits following the 25 ms signal.

The PFC has been implicated in the regulation of top-down attentional
processing via the cholinergic and glutamatergic systems (Nelson, Sarter, &
Bruno, 2005). The corticopetal cholinergic system of the basal forebrain aids in
sensory optimization that filters out interfering information such as distractors and
background noise, and receives glutamatergic and cholinergic input originating
from the PFC (Sarter, Givens, & Bruno, 2001). The orexin receptor antagonist
SB-334867 could affect PFC outputs to the basal forebrain, resulting in the shift
bias seen in the current data. The neurochemical basis for this shift in bias
remains unsettled.
Another explanation of the elevated detection of the 25 ms signal at the
1.0 mg/kg SB-334867 dose can be found in dopamine-related research.
Amphetamine-induced dopamine release has been shown to increase the number
of hits at the shortest signal duration (also 25 ms) by an average o f 20% on the
attention task used in the present study (Deller & Sarter, 1998), which is similar
the results found in this study. No changes at the longer signal durations (500 ms
and 50 ms) were found. Deller and Sarter (1998) suggested that behavioral
sensitization caused by repeated exposure to amphetamines led to the increase in
signal detection at the shortest duration. Orexin A within the ventral tegmental
area has been implicated in having a critical role in behavioral sensitization after
cocaine exposure (Borgland, Taha, Sarti, Fields, & Bonci, 2006). While this
evidence suggests that a link between orexins and the dopamine system could
account, at least in part, for the results found in the current study, amphetamine
administration also led to an increase in false alarms, which was not observed in
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the current study. Thus, the cause of the increased hit rate at the 25 ms signal
duration remains speculative.
Future research into the link between dopamine and orexins would be
beneficial in explaining the results found in the present study. While orexins
seem to regulate dopamine release within several brain regions, a clear cut pattern
of effect has not been established. Infusions of an orexin antagonist into the
ventral tegmental area during the attention task would assess the specific effects
o f the drug on the dopaminergic neurons in this region. Recent research has
suggested that dopamine negatively modulates acetylcholine release in the basal
forebrain via the PFC-nucleus accumbens pathway (Brooks, Sarter, & Bruno,
2007). However, the interaction between dopamine and ACh, as well as the
neural circuits involved, needs to be explored in more depth.
Experiment 2
One of the limitations of Experiment 1 was that i.p. injections were
used, causing the drug spread throughout the brain and the periphery, making it
difficult to know which neurotransmitter systems were affected and how this, in
turn, affected task performance. To address this, as well as to explore
acetylcholine’s role in Experiment 1’s results, Experiment 2 was designed to
assess the effects of localized infusions of SB-334867 into the basal forebrain.
Methods
Subjects. Subjects were 11 male Long-Evans rats, approximately two
months old at the beginning of the experiment (Charles River Laboratories, Inc.,
Wilmington, MA). All animals were experimentally nai've. Animal housing and
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care procedures were identical to those described in Experiment 1. The
experimental protocol was approved by the Institutional Animal Care and Use
Committee at the College o f William and Mary, and all animals were handled
according to Guidelines for the Care and Use o f Laboratory Animals as set forth
by the National Institutes of Health (National Research Council, 1996).
Apparatus and behavioral training procedures. The experimental
apparatus and training procedures used were identical to those described in
Experiment 1. The animals were trained on this task until the criterion of 70%
hits on the 500 ms signal and 70% correct rejections for three consecutive
sessions was met.
Surgical procedures. After reaching baseline criterion in the attention
task, animals received bilateral intrabasalis guide cannulae implantations. Prior to
surgery, rats received 2.7 mg/ml acetaminophen diluted in water overnight.
Animals were anesthetized using intraperitoneal (i.p.) injections of 90.0 mg/kg
ketamine and 9.0 mg/kg xylazine. Animals were shaved using an electric razor,
and placed in a stereotaxic device (Kopf Instruments, Tujunga, CA) with the
incisor bar set 3.3mm below the interaural line (IA). An incision was made along
the midline from anterior to posterior, exposing the skull. Holes were made over
the target coordinates for guide cannulae implantation (AP: -1.3, ML: +/- 2.7 from
bregma; DV: +3.5 from IA). Eight mm guide cannulae were used, with internal
cannulae extending 1 mm beyond the guide cannulae. Three jeweler’s screws
were also inserted into the skull. Dental cement was used to secure guide
cannulae placement. Dummy cannulae were inserted to prevent clogging. Rats
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were given free access to food and water for one week after surgery, after which
the rats were returned to water restriction and began to retrain on the task. Once
the rats reached reestablished performance criterion, infusion procedures began.
Procedures fo r SB-334867 infusions. The vehicle solution and preparation
procedures were identical to those described in Experiment 1. The rats received
four drug doses: vehicle solution, 0.15 pg/pl, 0.3 pg/pl, and 0.6 pg/pl SB-334867,
in a counterbalanced order. Infusions were given through an internal cannulae
attached to a 1.0 pi Hamilton syringe via polyethylene tubing at a rate of 0.5
pl/minute (0.5 pi per hemisphere). Due to technical difficulties, a subset of
animals (N=7) received all infusion types at a rate of 1.0 pl/minute. All infusions
were administered immediately prior to each testing session. At least two days of
behavioral training took place between each infusion to reestablish baseline task
performance.
Histological procedures. Rats were deeply anesthetized with 90.0 mg/kg
ketamine and 9.0 mg/kg xylazine. Rats were then transcardially perfused with
10% sucrose and 10% formalin at a pressure of 300mmHg using a Perfusion One
instrument (myneurolab.com, St. Louis, MO). The brains were then removed and
put into formalin for no more than 48 hours. The tissue was then put into a 30%
sucrose solution in phosphate-buffered saline for at least three days. The tissue
was then frozen and sectioned (40 pm) using a freezing microtome. Every
section was saved and mounted. The tissue was then stained using cresyl violet.
Slides were analyzed using an Olympus BX-51 Research microscope to assess
cannulae placement.
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Behavioral measures and statistical analyses. The behavioral measures
used in Experiment 2 were the same as those used in Experiment 1. As in
Experiment 1, the relative number of hits, correct rejections, and omissions were
analyzed using repeated-measures analysis o f variances (ANOVA).
Results
Histological analyses. Analyses confirmed that cannulae were correctly
placed in ten animals. Only these animals were included in the analyses. The tips
of the guide cannulae were located approximately 1 mm above the target brain
region. Internal cannulae extended 1 mm beyond the ends of the guide cannulae.
Among the animals included in the statistical analyses, only minor variations in
placement were observed.
Statistical analyses. This study assessed the effects of intrabasalis
infusions of the orexin antagonist SB-334867 on attentional performance. One
animal was discarded from behavioral data analysis due to incorrect cannulae
placement. The data reported here are from the ten rats with cannulae located
within the basal forebrain. A repeated-measures ANOVA on the relative number
of hits for the three signal durations found a main effect for signal duration
(F(2,18) = 113.73,/? < 0.001). Rats exhibited a signal duration-dependent
accuracy, with the hit rate higher following longer signal durations. For hits, no
significant main effects were found for dose or block (p = 0.84 andp = 0.56) (see
Figure 4).
In addition, no significant interactions were found. However, inspection
o f the means revealed some trends concerning the effects of drug administration

25

on the hit rate, mainly during the third block of trials within a session. The
relative number o f hits following the 500 ms signal duration for the third block of
trials following the 0.6 pi SB dose was slightly lower for the third block following
vehicle administration (see Figure 5). However, exploratory /-tests comparing
signal detection during the third block following vehicle and the 0.6 pG/side
infusion did not find any significant effects.
A repeated measures ANOVA on the relative number of correct rejections
found a significant main effect for block (F(2,18) = 7.26,/? < 0.01) (see Figure 6).
Rats exhibited a higher correct rejection rate during the second block of trials as
compared to the first and third blocks. No other significant main effects or
interactions were found for correct rejections. Overall, no differences in
performance on non-signal trials were found between dose levels (see Figure 7).
In addition, no significant effects were found for omissions.
Discussion
Experiment 2 investigated the specific action o f orexins within the basal
forebrain on attentional performance in rats. Intrabasalis infusions of the orexin-1
receptor antagonist SB-334867 did not result in any significant dose-related
results. Significant main effects for signal duration were found, in that rats
performed better at the longer signal durations compared to the shorter signal
durations. However, these effects were expected on this task and remained
constant across dose. Signal detection at the 500 ms signal duration tended to be
lower during the third block of trials following the 0.6 mg/pL dose, however this
effect was not significant. It is possible that the highest dose o f SB-334867 could
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have caused a vigilance decrement after prolonged attentional performance.
Deficits in attention performance have been found in humans as a function of time
(Paus, Zatorre, Hofle, Caramanos, Gotman, Petrides, & Evan, 1997). Participants
showed decreased correct responses and increased reaction time during a 60
minute auditory attention task. In addition, there was a decrease in cerebral blood
flow to the substantia innominata, a region of the basal forebrain. More specific
to the current attention task, high event rates and lower intensity signals have been
shown to perpetuate a vigilance decrement on signal trials (McGaughy & Sarter,
1995; Bushnell, 1999).
A significant main effect was found for block during non-signal trials.
Rats performed better during the second block of trials as compared to the first
and third blocks. This pattern could be due in part to a “warm up” effect
following the infusion procedure. This effect can be observed as the rats
performing more poorly during the beginning of a testing session as compared to
later trials. In addition, vigilance could deteriorate after prolonged task
performance, resulting in the decreased rate of correct rejections during the third
block o f trials, similar to the trend found during the third block following the 500
ms signal duration after the highest dose.
General Discussion
The first experiment was designed to assess the overall effects o f the
orexin-1 receptor antagonist SB-334867 on attentional performance via the use of
systemic injections. However, it is unknown how much of the drug was absorbed
in the periphery. The orexin-1 receptor antagonist affected many brain areas, not
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just regions specialized for attention. To address this problem, the second
experiment was designed to investigate the effects of localized infusions of SB334867 into the basal forebrain. These infusions did not produce the effects
observed in Experiment 1. One suggestion would be to use higher doses o f SB334867. However, the doses used are within the range of those previously shown
to increase wakefulness (Thakkar, Ramesh, Strecker, & McCarley, 2001). In
addition, Fadel and colleagues (2005) showed increased cortical ACh efflux after
0.1 pM infusions. Due to the trend found during the third block following the 500
ms signal duration after the 0.6 pg infusion, increasing the time between the
initial infusion and onset of behavioral training might uncover significant
attentional deficits. However, it is not know if the trend observed is due simply to
time after the initial drug infusion, if orexin’s actions within the basal forebrain
interact with time-on-task, or simply due to the increasing number of trials. It is
also possible that the changes in signal detection seen in Experiment 1 are due to
SB-334867’s action in a brain area other than the basal forebrain or on a different
neurotransmitter system, such as glutamate or GABA.
The PFC is important for attention processing, and receives cholinergic
projections from the basal forebrain (Fadel et al., 2005). Intrabasalis infusions of
orexin A have been shown to increase ACh efflux within the PFC. While no
significant dose-related results were found in Experiment 2, a microdialysis study
might be useful in monitoring the effect of the orexin-1 antagonist on cholinergic
levels in the PFC during the task. Previous microdialysis research (Fadel et al,
2005) found that infusions of orexin A increased ACh efflux within the cortex,
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suggesting that a similar pattern would be found during task performance on an
ACh-dependent task. An orexin-1 receptor antagonist such as SB-334867 would
block this efflux of ACh, perhaps keeping ACh at lower levels (perhaps similar to
those seen during non-attenionally demanding tasks by Burk & Sarter, 2001).
The statistical power of the present experiments is also limited due to the
small number of subjects used in both cases. In Experiment 1, a larger number of
animals may have revealed a significant increase in signal detection following a
25 ms signal at the highest dose of SB-334867. In Experiment 2, there was quite
a bit of variability among subjects, specifically with the number of omissions at
the higher doses of SB-334867. The standard error for overall omissions
following the vehicle dose was 3.69 (calculated as SD/V(10), where SD is the
standard deviation of the sample). The standard error for overall omissions
following the 0.6 pG/side infusion was 13.77. There was also a high level of
variability for hits across blocks in Experiment 2 as compared to the hits in
Experiment 1. This variability could be a result o f SB-334867 administration
(though not found to be significant as a function of dose); it could also be
obscuring any effects the drug might have had. A larger number of animals could
result in more clear cut patterns within the data.
In summary, systemic injections of orexin-1 receptor antagonist SB334867 did decrease performance on an attention task in the hypothesized
manner. Detection o f the 500 ms signal was lower following the highest dose (5.0
mg/kg) o f SB-334867 compared to vehicle administration. In addition, signal
detection of the shortest signal duration (25 ms) was significantly improved at the
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1.0 mg/kg dose. No significant dose-dependent results were found following
intrabasalis infusions of SB-334867. Thus, it is likely that orexin’s interaction
with another neural system, such as the dopaminergic pathway in the PFC,
contributed to the current results. The present data offer a starting point into
understanding the relationship between orexins and the cholinergic system during
an attention task.
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Figure Caption
Figure 1. Correct detection o f the 500 ms signal was decreased following the
highest dose (5.0 mg/kg SB-334867) as compared to vehicle administration.
Figure 2. Correct detection of the 25 ms signal was increased following the 1.0
mg/kg dose of SB-334867 as compared to vehicle administration.
Figure 3. The percentage o f correct rejections was not significantly affected by
administration of SB.334867.
Figure 4. Overall, correction detection of signals was not affected by dose.
Figure 5. A decrease in signal detection at the 500 ms signal duration was present
following the 0.6 pg/pl infusion of SB-334867. This effect was not significant (p
> 0.05).
Figure 6. The percentage of correct rejections was increased during the second
block o f trials as compared to the first and second block of trials. This effect was
not affected by SB-334867 dose. * Indicatesp < 0.01.
Figure 7. The overall percentage of correct rejections was not significantly
affected by intrabasalis infusions of SB-334867.
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